Home › Companies › VANDA PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and VANDA PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 17, 2024: 5 items on VANDA PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024: 1 elected · 3 approved · 1 failed (calculated).
Significant dissent: 2 directors (53.2%, 20.8% against).
Notable dissent: 1 say-on-pay vote (78.7% support); 1 other board item (19.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore VANDA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are VANDA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mihael H. Polymeropoulos, M.D. | 33,976,239 | 8,943,623 | 133,346 | -- | 4,923,082 | 79% | Elected | — |
| Elect Director: Phaedra S. Chrousos | 20,071,828 | 22,780,322 | 201,058 | -- | 4,923,082 | 46.8% | Failed (calculated) | — |
| 2. Ratification of Selection of PricewaterhouseCoopers LLP | 44,750,588 | 1,739,295 | 1,486,407 | -- | -- | 96% | Approved | — |
| 3. Advisory Vote on Named Executive Officer Compensation | 33,515,119 | 9,093,168 | 444,921 | -- | 4,923,082 | 79% | Approved | — |
| 4. Amendment to the 2016 Plan | 34,411,032 | 8,565,705 | 76,471 | -- | 4,923,082 | 80% | Approved | — |
Source: VANDA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
172 asset managers disclosed a vote on at least one VANDA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III Directors: Mihael H. Polymeropoulos, M.D.
VANDA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mihael H. Polymeropoulos, M.D.”): 33,976,239 for, 8,943,623 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class III directors until the Company's 2027 annual meeting of stockholders.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 13,272,533 for, 1,588,593 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,349,028 | 0 | 0 | 0 | For |
| Vanguard | 3,328,613 | 0 | 0 | 0 | For |
| Fidelity | 1,299,299 | 114,584 | 0 | 0 | Mixed |
| Dimensional | 0 | 1,264,595 | 0 | 0 | Against |
| Federated Hermes | 675,517 | 0 | 0 | 0 | For |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| SEI | 514,282 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 355,100 | 0 | 0 | 0 | For |
| Invesco | 312,539 | 0 | 0 | 0 | For |
| Nationwide | 258,449 | 0 | 0 | 0 | For |
| American Century | 252,388 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 243,986 | 0 | 0 | 0 | For |
| Victory Capital | 216,717 | 0 | 0 | 0 | For |
| EA Series Trust | 204,981 | 0 | 0 | 0 | For |
| Equitable | 190,562 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,077 | 0 | 0 | 0 | For |
| Goldman Sachs | 155,923 | 0 | 0 | 0 | For |
| TIAA | 0 | 153,314 | 0 | 0 | Against |
| MFS | 141,053 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 104,632 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 79,930 | 0 | 0 | 0 | For |
| GuideStone | 72,061 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,181 | 8,874 | 0 | 0 | Mixed |
| ALPS ETF Trust | 40,269 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
46.8% Majority: no · of votes cast
Description as filed by funds: To elect two Class III Directors: Phaedra S. Chrousos
VANDA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Phaedra S. Chrousos”): 20,071,828 for, 22,780,322 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Failed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for did not exceed votes against.
Support: 46.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 10,547,952 for, 4,313,174 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,349,028 | 0 | 0 | 0 | For |
| Vanguard | 3,315,613 | 13,000 | 0 | 0 | For |
| Fidelity | 1,292,599 | 121,284 | 0 | 0 | Mixed |
| Dimensional | 0 | 1,264,595 | 0 | 0 | Against |
| Federated Hermes | 675,517 | 0 | 0 | 0 | For |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| SEI | 514,282 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 355,100 | 0 | 0 | Against |
| Invesco | 0 | 312,539 | 0 | 0 | Against |
| Nationwide | 0 | 258,449 | 0 | 0 | Against |
| American Century | 0 | 252,388 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 243,986 | 0 | 0 | Against |
| Victory Capital | 0 | 216,717 | 0 | 0 | Against |
| EA Series Trust | 0 | 204,981 | 0 | 0 | Against |
| Equitable | 97,889 | 92,673 | 0 | 0 | Mixed |
| Prudential/PGIM | 177,077 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 155,923 | 0 | 0 | Against |
| TIAA | 0 | 153,314 | 0 | 0 | Against |
| MFS | 0 | 141,053 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 104,632 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 79,930 | 0 | 0 | 0 | For |
| GuideStone | 0 | 72,061 | 0 | 0 | Against |
| TARGET PORTFOLIO TRUST | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 56,055 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 40,269 | 0 | 0 | Against |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
80% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's amended and restated 2016 Equity Incentive Plan, as amended (the "2016 Plan"), to increase the aggregate number of shares authorized for issuance under the 2016 Plan.
VANDA PHARMACEUTICALS INC.’s own tally for this item (“4. Amendment to the 2016 Plan”): 34,411,032 for, 8,565,705 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 13,504,770 for, 1,356,356 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,349,028 | 0 | 0 | 0 | For |
| Vanguard | 3,328,613 | 0 | 0 | 0 | For |
| Fidelity | 1,413,883 | 0 | 0 | 0 | For |
| Dimensional | 1,264,595 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 675,517 | 0 | 0 | Against |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| SEI | 514,282 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 355,100 | 0 | 0 | 0 | For |
| Invesco | 312,539 | 0 | 0 | 0 | For |
| Nationwide | 258,449 | 0 | 0 | 0 | For |
| American Century | 0 | 252,388 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 243,986 | 0 | 0 | Against |
| Victory Capital | 216,717 | 0 | 0 | 0 | For |
| EA Series Trust | 204,981 | 0 | 0 | 0 | For |
| Equitable | 190,562 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,077 | 0 | 0 | 0 | For |
| Goldman Sachs | 155,923 | 0 | 0 | 0 | For |
| TIAA | 153,314 | 0 | 0 | 0 | For |
| MFS | 0 | 141,053 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 104,632 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 79,930 | 0 | 0 | 0 | For |
| GuideStone | 72,061 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 56,055 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 40,269 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
79% Approved · of votes cast
Prior year: 96.8% for (June 8, 2023 meeting) ▼ 18.2 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.
VANDA PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Named Executive Officer Compensation”): 33,515,119 for, 9,093,168 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved on an advisory, non-binding basis the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,349,028 | 0 | 0 | 0 | For |
| Vanguard | 3,328,613 | 0 | 0 | 0 | For |
| Fidelity | 1,413,883 | 0 | 0 | 0 | For |
| Dimensional | 1,264,595 | 0 | 0 | 0 | For |
| Federated Hermes | 675,517 | 0 | 0 | 0 | For |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| SEI | 514,282 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 355,100 | 0 | 0 | Against |
| Invesco | 0 | 312,539 | 0 | 0 | Against |
| Nationwide | 258,449 | 0 | 0 | 0 | For |
| American Century | 0 | 252,388 | 0 | 0 | Against |
| Columbia Threadneedle | 243,986 | 0 | 0 | 0 | For |
| Victory Capital | 216,717 | 0 | 0 | 0 | For |
| EA Series Trust | 204,981 | 0 | 0 | 0 | For |
| Equitable | 190,562 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,077 | 0 | 0 | 0 | For |
| Goldman Sachs | 155,923 | 0 | 0 | 0 | For |
| TIAA | 153,314 | 0 | 0 | 0 | For |
| MFS | 141,053 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 104,632 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 79,930 | 0 | 0 | 0 | For |
| GuideStone | 72,061 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 56,055 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 40,269 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 13,928,619 for, 932,507 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,302,050 | 170 | 0 | 0 | For |
| Renaissance | 3,005,477 | 0 | 0 | 0 | For |
| DE Shaw | 1,362,846 | 0 | 0 | 0 | For |
| TANG CAPITAL MANAGEMENT LLC | 0 | 1,282,341 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,272,823 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,254,778 | 0 | 0 | 0 | For |
| State Street | 1,131,323 | 4,744 | 0 | 0 | For |
| Prudential/PGIM | 930,930 | 12,400 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 899,184 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 808,398 | 0 | 0 | 0 | For |
| Federated Hermes | 687,026 | 3,290 | 0 | 0 | For |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 602,788 | 0 | 0 | 0 | For |
| SEI | 516,687 | 0 | 0 | 0 | For |
| Northern Trust | 439,919 | 2,847 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 441,152 | 0 | 0 | 0 | For |
| Wellington | 390,737 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 355,100 | 0 | 0 | Against |
| APG Asset Management US Inc. | 0 | 0 | 354,500 | 0 | Abstain |
| Invesco | 0 | 327,372 | 0 | 0 | Against |
| Allianz | 0 | 322,386 | 0 | 0 | Against |
| Two Sigma | 298,397 | 0 | 0 | 0 | For |
| Dimensional | 298,372 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 270,431 | 0 | 0 | 0 | For |
| American Century | 0 | 252,388 | 0 | 0 | Against |
Institutional-manager reports, all 129 managers: 20,907,994 for, 2,877,525 against, 354,500 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024.
VANDA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of PricewaterhouseCoopers LLP”): 44,750,588 for, 1,739,295 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 14,655,976 for, 205,150 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,349,028 | 0 | 0 | 0 | For |
| Vanguard | 3,328,613 | 0 | 0 | 0 | For |
| Fidelity | 1,413,883 | 0 | 0 | 0 | For |
| Dimensional | 1,264,595 | 0 | 0 | 0 | For |
| Federated Hermes | 675,517 | 0 | 0 | 0 | For |
| Charles Schwab | 668,861 | 0 | 0 | 0 | For |
| SEI | 514,282 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 355,100 | 0 | 0 | 0 | For |
| Invesco | 312,539 | 0 | 0 | 0 | For |
| Nationwide | 258,449 | 0 | 0 | 0 | For |
| American Century | 252,388 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 243,986 | 0 | 0 | 0 | For |
| Victory Capital | 216,717 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 204,981 | 0 | 0 | Against |
| Equitable | 190,562 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,077 | 0 | 0 | 0 | For |
| Goldman Sachs | 155,923 | 0 | 0 | 0 | For |
| TIAA | 153,314 | 0 | 0 | 0 | For |
| MFS | 141,053 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 104,632 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 79,930 | 0 | 0 | 0 | For |
| GuideStone | 72,061 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 56,055 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 40,269 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,196,523 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 5.75% |
| 2 | Vanguard | 5.72% |
| 3 | Fidelity | 2.43% |
| 4 | Dimensional | 2.17% |
| 5 | Federated Hermes | 1.16% |
| 6 | Charles Schwab | 1.15% |
| 7 | SEI | 0.88% |
| 8 | BRIDGEWAY FUNDS INC | 0.61% |
| 9 | Invesco | 0.54% |
| 10 | Nationwide | 0.44% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 5.67% |
| 2 | Renaissance | 5.16% |
| 3 | DE Shaw | 2.34% |
| 4 | TANG CAPITAL MANAGEMENT LLC | 2.20% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.19% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 2.16% |
| 7 | State Street | 1.95% |
| 8 | Prudential/PGIM | 1.62% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.55% |
| 10 | Nantahala Capital Management, LLC | 1.39% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock, Inc. | 8,346,367 | 14.34% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Renaissance Technologies LLC | 3,681,125 | 6.33% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Vanguard Group | 3,587,139 | 6.16% | Form 13F, quarter ended March 31, 2024 |
| Mihael H. Polymeropoulos, M.D. | 2,739,017 | 4.71% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| D.E. Shaw | 1,802,842 | 3.10% | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 1,721,635 | 2.96% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,245,382 | 2.14% | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,203,295 | 2.07% | Form 13F, quarter ended March 31, 2024 |
| Citadel Advisors | 800,539 | 1.38% | Form 13F, quarter ended March 31, 2024 |
| Charles Schwab | 668,180 | 1.15% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 58,196,523 shares outstanding, as reported by VANDA PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At VANDA PHARMACEUTICALS INC.'s shareholder meeting held May 17, 2024, in the 2023-2024 proxy season, 172 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,088 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION. — VANDA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 79% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VANDA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VANDA PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
VANDA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “VANDA PHARMACEUTICALS (VNDA) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/vanda-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.